Biomedical subjects

F M Müller

Publications and source records attributed to F M Müller.

22 records · Page 2Linked to original sources

PubMed1993

Cerebral malformation, seizures, hypertrichosis, distinct face, claw hands, and overlapping fingers in sibs of both sexes.

We report on sibs of both sexes with a multiple malformation syndrome of cerebral malformation, seizures, hypertrichosis, distinct face, claw hands, and overlapping fingers. The older boy died in a tonic extension spasm at age 4 months. When discharged, the younger girl was 3.5 months old. This appears to be an autosomal recessive syndrome which to our knowledge has not been described before.

Abnormalities, Multiple↗

PubMedDate not supplied

[Diarrhea in 1,337 children of the Mainz University Clinic: Importance of Salmonella and rotaviruses].

In Germany, infectious diseases cause little mortality, but they are responsible for a large proportion of morbidity. In order to obtain data about the relevance of infectious diarrhea, the charts of 1337 outpatients, hospitalized for this disorder in the time between 1986-1989 at the Children's Hospital, Johannes Gutenberg University Mainz, were analyzed. Sixty-seven percent of patients were younger than one year. An offending organism could be isolated in 42.1% of patients, with Rotaviruses being the leading cause of diarrhea (415 cases), followed by Salmonella spp. (130 cases). Rotavirus-disease was mainly seen in winter, Salmonella-disease in late summer and in autumn. Severe courses of diarrhea were rare, no patient died. Mean duration of hospitalization was 7 days, independent from the offending organism. Infectious diarrhea is a common disorder in children in Germany, which may lead to hospitalization especially during infancy. Additional epidemiological studies are needed in order to develop effective control measures.

Adolescent↗

PubMedDate not supplied

[Progress in prevention and therapy of infectious complications in children and adolescents with neoplastic diseases].

Due to the high dose-intensity of most current treatment protocols, the growing number of marrow transplantations, the routine use of aggressive supportive care and certain pathogen-related problems, infections remain an important cause for morbidity and mortality in children and adolescents with cancer. Over the last decade, however, considerable progress has been made in diagnosis, prevention and treatment of infectious complications in the immunocompromised host. This article first delineates both clinical approach and current treatment strategies in the pediatric cancer patient presenting with neutropenia and fever of unknown origin. It then reviews diagnosis and treatment of the most common specific infections and concludes with a discussion of preventive measures in the setting of anticancer treatment.

Adolescent↗

PubMedDate not supplied

Lipid formulations of amphotericin B: clinical perspectives for the management of invasive fungal infections in children with cancer.

During the past four decades, amphotericin B deoxycholate has been the cornerstone of systemic chemotherapy for life-threatening fungal infections. Despite a broad spectrum of antifungal activity, its utility is greatly hampered by renal toxicity and limited clinical efficacy, in particular in patients with profound and persistent neutropenia. The novel lipid formulations of amphotericin B have distinct physicochemical properties resulting in different distribution patterns. Nevertheless, they all share a considerable reduction of nephrotoxicity, which allows for the delivery of higher daily dosages of amphotericin B. Preliminary efficacy data indicate that these compounds are overall at least as effective as amphotericin B deoxycholate. However, information for children is limited, and comparative studies for their use as first line agents are only in their beginnings. In this article, we review the clinical pharmacokinetics, safety, and efficacy of the lipid formulations of amphotericin B with special emphasis on pediatric data, and we seek to provide a rational framework for the determination of their current role in patients with cancer and proven or suspected invasive fungal infections.

Amphotericin B↗